Targeting Discoidin Domain Receptor 2 for the Development of Disease-Modifying Osteoarthritis Drugs | Zendy

Xiao Li | Zendy; Chenlu Liu | Zendy; Beiyu Wang | Zendy; Fei Wei | Zendy; Yandong Mu | Zendy; Lin Xu | Zendy; Yefu Li | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Targeting Discoidin Domain Receptor 2 for the Development of Disease-Modifying Osteoarthritis Drugs

Author(s) -

Xiao Li,

Chenlu Liu,

Beiyu Wang,

Fei Wei,

Yandong Mu,

Lin Xu,

Yefu Li

Publication year - 2019

Publication title -

cartilage

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.705

H-Index - 33

eISSN - 1947-6043

pISSN - 1947-6035

DOI - 10.1177/1947603519852401

Subject(s) - discoidin domain , osteoarthritis , medicine , drug development , disease , drug , receptor tyrosine kinase , pharmacology , cancer research , bioinformatics , receptor , pathology , biology , alternative medicine

One of the most pressing issues in osteoarthritis (OA) research is the development of disease-modifying OA drugs (DMOADs), as currently there are no such drugs available. The paucity of suitable DMOADs is mostly due to the lack of approved ideal therapeutic targets necessary for the development of these drugs. However, based on recent discoveries from our laboratory and other independent laboratories, it is indicated that a cell surface receptor tyrosine kinase for collagen type II, discoidin domain receptor 2 (DDR2), may be an ideal therapeutic target for the development of DMOADs. In this article, we review the current status of research in understanding roles of DDR2 in the development of OA.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research